Marc Debled

8.1k total citations · 1 hit paper
121 papers, 3.8k citations indexed

About

Marc Debled is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marc Debled has authored 121 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 50 papers in Cancer Research and 46 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marc Debled's work include Breast Cancer Treatment Studies (47 papers), Advanced Breast Cancer Therapies (29 papers) and HER2/EGFR in Cancer Research (27 papers). Marc Debled is often cited by papers focused on Breast Cancer Treatment Studies (47 papers), Advanced Breast Cancer Therapies (29 papers) and HER2/EGFR in Cancer Research (27 papers). Marc Debled collaborates with scholars based in France, United States and Belgium. Marc Debled's co-authors include Gaëtan MacGrogan, Véronique Brouste, L. Mauriac, Simone Mathoulin‐Pélissier, C. Tunon de Lara, Thomas Bachelot, Carine Bellera, M. Durand, Sophie Abadie‐Lacourtoisie and Anne Floquet and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Marc Debled

113 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

2012 539 citations Thomas Bachelot, C. Bourgier et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Debled France	30	1.9k	1.5k	1.1k	716	662	121	3.8k
Agustí Barnadas Spain	34	2.0k 1.1×	1.2k 0.8×	789 0.7×	1.6k 2.3×	482 0.7×	141	4.1k
J.W.R. Nortier Netherlands	44	3.5k 1.8×	1.9k 1.2×	1.2k 1.1×	952 1.3×	783 1.2×	157	7.8k
Karen Gelmon Canada	18	2.1k 1.1×	1.9k 1.3×	705 0.7×	673 0.9×	813 1.2×	29	4.2k
M. Namer France	29	2.4k 1.3×	1.4k 0.9×	982 0.9×	562 0.8×	302 0.5×	122	3.7k
Mark L. Graham United States	26	2.2k 1.1×	1.7k 1.1×	574 0.5×	1.3k 1.8×	741 1.1×	53	4.5k
Florence Dalenc France	33	2.6k 1.4×	1.3k 0.9×	1.6k 1.5×	1.3k 1.9×	200 0.3×	209	4.5k
I E Smith United Kingdom	23	1.8k 0.9×	1.5k 1.0×	657 0.6×	777 1.1×	457 0.7×	59	3.5k
Diana Crivellari Italy	37	3.3k 1.7×	2.1k 1.4×	1.2k 1.1×	694 1.0×	736 1.1×	152	4.9k
Olivia Pagani Switzerland	42	3.4k 1.8×	1.8k 1.2×	1.5k 1.4×	667 0.9×	435 0.7×	159	5.5k
Bent Ejlertsen Denmark	44	3.9k 2.0×	2.8k 1.9×	1.2k 1.1×	1.3k 1.8×	754 1.1×	252	6.4k

Countries citing papers authored by Marc Debled

Since Specialization

Citations

This map shows the geographic impact of Marc Debled's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Debled with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Debled more than expected).

Fields of papers citing papers by Marc Debled

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Debled. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Debled. The network helps show where Marc Debled may publish in the future.

Co-authorship network of co-authors of Marc Debled

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Debled. A scholar is included among the top collaborators of Marc Debled based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Debled. Marc Debled is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frenel, Jean‐Sébastien, Amélie Lusque, Suzette Delaloge, et al.. (2023). Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British Journal of Cancer. 128(11). 2072–2080. 3 indexed citations

Béchade, Dominique, Carine Bellera, Pippa McKelvie‐Sebileau, et al.. (2022). Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies. Clinics and Research in Hepatology and Gastroenterology. 46(5). 101912–101912. 2 indexed citations

Darbo, Élodie, Marc Debled, Véronique Brouste, et al.. (2022). An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. ESMO Open. 7(4). 100502–100502. 8 indexed citations

Gal, Jocelyn, G. Milano, Patrick Brest, et al.. (2020). VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals. 13(11). 414–414. 7 indexed citations

Carton, Matthieu, Luc Cabel, Anne Patsouris, et al.. (2020). 281MO Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Annals of Oncology. 31. S353–S353. 2 indexed citations

Lerebours, Florence, Marina Pulido, Emmanuelle Fourme, et al.. (2020). Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials. British Journal of Cancer. 122(6). 759–765. 13 indexed citations

Debled, Marc, Valérie Velasco, C. Tunon de Lara, et al.. (2019). Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 179(1). 11–23. 32 indexed citations

Pistilli, Barbara, Audrey Lardy-Cléaud, Emmanuelle Jacquet, et al.. (2017). FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis. Annals of Oncology. 28. v92–v93. 1 indexed citations

Royce, Melanie, Mustafa Özgüroğlu, Thomas Bachelot, et al.. (2016). BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC). Annals of Oncology. 27. vi68–vi68. 11 indexed citations

10.

Pivot, X., Gilles Romieu, Marc Debled, et al.. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet Oncology. 14(8). 741–748. 211 indexed citations

11.

Bachelot, Thomas, C. Bourgier, Claire Cropet, et al.. (2012). Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology. 30(22). 2718–2724. 539 indexed citations breakdown →

12.

Boisserie-Lacroix, M., et al.. (2012). Radiological features of triple-negative breast cancers (73 cases). Diagnostic and Interventional Imaging. 93(3). 183–190. 52 indexed citations

13.

Boisserie-Lacroix, M., et al.. (2012). The inflammatory breast: Management, decision-making algorithms, therapeutic principles. Diagnostic and Interventional Imaging. 93(2). 126–136. 7 indexed citations

14.

Toulmonde, Maud, Nicolas Madranges, Véronique Brouste, et al.. (2012). Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Research and Treatment. 134(1). 325–332. 13 indexed citations

15.

Debled, Marc, Gaëtan MacGrogan, Véronique Brouste, et al.. (2010). Is it useful to detect lymphovascular invasion in lymph node‐positive patients with primary operable breast cancer?. Cancer. 116(13). 3093–3101. 29 indexed citations

16.

Crémoux, Patricia de, Marc Debled, Hervé Bonnefoi, & Paul Cottu. (2010). Marqueurs biologiques de résistance à l'hormonothérapie dans les cancers du sein. Bulletin du Cancer. 97(8). 951–963. 2 indexed citations

17.

Mauriac, L., Aparna Keshaviah, Marc Debled, et al.. (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology. 18(5). 859–867. 106 indexed citations

18.

Debled, Marc, Nadine Houédé, Nicolas Madranges, et al.. (2007). Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. British Journal of Cancer. 97(12). 1642–1647. 11 indexed citations

19.

Mauriac, L., Marc Debled, M. Durand, et al.. (2002). Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Annals of Oncology. 13(2). 293–298. 23 indexed citations

20.

Debled, Marc, Alain Ravaud, E Stöckle, & Nguyen Binh Bui. (1997). Systemic adjuvant chemotherapy for soft tissue sarcomas. Bulletin du Cancer. 84(6). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact